Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Greenlee

Family Medicine Pensacola, FL Medical Doctor

NPI 1871685925 CMS profile 130634

1500 N Pace Blvd, Pensacola, FL 32505

Open in the dashboard

General payments

$234,581

251 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Greenlee of Pensacola, FL is reported in the CMS Open Payments database as having received $234,581 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,023 45
2024 General $40,650 31
2023 General $35,653 26
2022 General $31,878 24
2021 General $29,495 35
2020 General $31,907 42
2019 General $29,975 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Greenlee
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Samuel Greenlee were reported at $35,023. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Samuel Greenlee Family Medicine median Middle half National median
2019 $29,975 $150 $41–$543 $163
2020 $31,907 $120 $32–$415 $114
2021 $29,495 $137 $35–$551 $132
2022 $31,878 $137 $37–$512 $149
2023 $35,653 $149 $42–$545 $160
2024 $40,650 $156 $44–$560 $164
2025 $35,023 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $122,875 127 payments
  2. CSL Plasma Inc. $111,273 99 payments
  3. Pfizer Inc. $266 14 payments
  4. AbbVie, Inc. $41 2 payments
  5. Abbott Laboratories $31 2 payments
  6. GlaxoSmithKline, LLC. $31 2 payments
  7. Lilly USA, LLC $27 2 payments
  8. Jazz Pharmaceuticals Inc. $13 1 payment
  9. Novo Nordisk Inc $13 1 payment
  10. Teva Pharmaceuticals USA, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $234,148 226 payments
  2. Food and Beverage $432 25 payments
Products named General payments · program years 2019–2025
  1. COLOGUARD DNA CAPTURE REAGENTS $143 7 payments
  2. COLOGUARD $122 7 payments
  3. REYVOW $63 3 payments
  4. TRULICITY $27 2 payments
  5. SYNTHROID $23 1 payment
  6. FreeStyle Libre 2 $18 1 payment
  7. UBRELVY $18 1 payment
  8. TRELEGY ELLIPTA $17 1 payment
  9. SHINGRIX $14 1 payment
  10. BOOSTRIX $14 1 payment
  11. Other $108 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

791

Median for Family Practice: 1,826

Drug cost

$18,987

Median for Family Practice: $120,094

Branded share of claims

13%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Synthroid Levothyroxine Sodium Brand 28 $2,827
Lidocaine Generic 13 $2,484
Fentanyl Generic 12 $2,050
Albuterol Sulfate Hfa Albuterol Sulfate Brand 62 $1,847
Omeprazole Generic 63 $1,211
Diclofenac Sodium Generic 16 $974
Ventolin Hfa Albuterol Sulfate Brand 13 $692
Gabapentin Generic 28 $660
Ibuprofen Generic 51 $628
Cyclobenzaprine Hcl Generic 18 $572

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record